2022 Year in Review

January 10th, 2023

Dear CVPath Friends and Colleagues,

On behalf of everyone here at the CVPath Institute, it is my pleasure to wish you, your families, and your teams a happy, safe and productive New Year.

We would also like to thank you for your friendship and continued support of CVPath during 2022.  It has been a productive year for the Institute, including a number of noteworthy achievements and developments. Here are some highlights:

  • Dr. Virmani made’s list of Best Female Scientists. The international ranking includes leading female scientists from all major areas of science. Dr. Virmani ranked #36 in the world and #27 in the U.S. See for more information.
  • CVPath was awarded a contract by the National Institutes of Health and New York University to play a major role in the NIH’s RECOVER initiative, which seeks to understand more about the long-term effects of COVID. We are partnering with NYU and Howard University to collect autopsy specimens to learn more about the long-term effect of COVID-19 on the heart and other organs.
  • CVPath continues to play a major role in the Leducq Foundation’s Transatlantic Networks of Excellence Award, where we and multiple European and American collaborators seek to define the role of smooth muscle cells in Late Stage Atherosclerotic Plaque Pathogenesis.
  • Congratulations to Yu Sato, a CVPath fellow, who was awarded the inaugural Renu Virmani Research Scholar Award!  This award is given to a fellow at the Institute who shows extraordinary promise for a career in cardiovascular medicine.
  • On the publications front, CVPath researchers also had a very good year:
    1. In January, we published a review on Sex Differences in Coronary Atherosclerosis (
    2. In March, I was part of a team that published Design Principles and Outcomes Definitions for Device Based Therapies for Hypertension (
    3. In April, we published an original research letter describing our experience with Cerebral Embolic Capture Using the SENTINEL Device During Transcatheter Aortic Valve Implantation in Low to Intermediate Risk Patients: The SENTINEL LIR Study (
    4. In June, we published a review article about Generalized Arterial Calcification of Infancy (GACI) (
    5. In August, we published a review of the role of alternative macrophage phenotypes in human atherosclerosis (
    6. In October, we published an original research paper on the Translational Value of Preclinical Models for Renal Denervation (
    7. In November, we published an original research paper describing The relationships between neighborhood disadvantage and cardiovascular findings at autopsy in subjects with sudden death (

In the year ahead, watch for new research findings from CVPath in the fields of atherosclerosis biology, structural heart devices, drug-eluting devices, and polygenic-risk scores and human atherosclerosis. We intend once again to be energetic, entrepreneurial, meticulous—and productive.

Thank you again for your continued support of CVPath.  Dr. Virmani, and all our colleagues at the Institute, join me in looking forward to working with you in the New Year and wishing you a very happy one.  Please don’t hesitate to contact me with any questions or suggestions that you may have.


Aloke Finn, MD

Medical Director